Serco Group plc (SRP) Receives a Buy from RBC Capital
In a report released yesterday, Andrew Brooke from RBC Capital maintained a Buy rating on Serco Group plc (SRP – Research Report), with a price target of p230.00. The company's shares closed yesterday at p199.00.
Confident Investing Starts Here:
Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions
Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter
According to TipRanks, Brooke is a 3-star analyst with an average return of 1.5% and a 47.44% success rate. Brooke covers the Industrials sector, focusing on stocks such as Travis Perkins, Rentokil Initial, and Serco Group plc.
Serco Group plc has an analyst consensus of Strong Buy, with a price target consensus of p213.75, which is a 7.41% upside from current levels. In a report released yesterday, J.P. Morgan also maintained a Buy rating on the stock with a £1.95 price target.
SRP market cap is currently £1.96B and has a P/E ratio of 46.31.
Based on the recent corporate insider activity of 24 insiders, corporate insider sentiment is negative on the stock. This means that over the past quarter there has been an increase of insiders selling their shares of SRP in relation to earlier this year.
Try Our AI Features
Explore what Daily8 AI can do for you:
Comments
No comments yet...
Related Articles
Business Insider
2 hours ago
- Business Insider
Goldman Sachs Sticks to Its Buy Rating for Publicis Groupe (0FQI)
Goldman Sachs analyst Lisa Yang maintained a Buy rating on Publicis Groupe (0FQI – Research Report) yesterday and set a price target of €106.00. The company's shares closed yesterday at €95.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Yang covers the Communication Services sector, focusing on stocks such as ITV plc, WPP, and Prosus. According to TipRanks, Yang has an average return of 8.5% and a 59.36% success rate on recommended stocks. The word on The Street in general, suggests a Strong Buy analyst consensus rating for Publicis Groupe with a €112.20 average price target, implying a 18.11% upside from current levels. In a report released on June 25, Barclays also maintained a Buy rating on the stock with a €115.00 price target. Based on Publicis Groupe's latest earnings release for the quarter ending December 31, the company reported a quarterly revenue of €8.38 billion and a net profit of €885 million. In comparison, last year the company earned a revenue of €7.7 billion and had a net profit of €689 million
Business Insider
2 hours ago
- Business Insider
Maxim Group Reaffirms Their Hold Rating on Aethlon Medical (AEMD)
In a report released yesterday, Anthony Vendetti from Maxim Group maintained a Hold rating on Aethlon Medical (AEMD – Research Report). The company's shares closed yesterday at $1.25. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter Vendetti covers the Healthcare sector, focusing on stocks such as Dermata Therapeutics, bioAffinity Technologies, Inc., and Helius Medical Technologies. According to TipRanks, Vendetti has an average return of -27.0% and a 23.28% success rate on recommended stocks. The word on The Street in general, suggests a Hold analyst consensus rating for Aethlon Medical.
Business Insider
2 hours ago
- Business Insider
Goldman Sachs Sticks to Its Buy Rating for Philogen SpA (78Q)
In a report released yesterday, Rajan Sharma from Goldman Sachs maintained a Buy rating on Philogen SpA (78Q – Research Report), with a price target of €29.00. The company's shares closed yesterday at €23.00. Confident Investing Starts Here: Easily unpack a company's performance with TipRanks' new KPI Data for smart investment decisions Receive undervalued, market resilient stocks right to your inbox with TipRanks' Smart Value Newsletter According to TipRanks, Sharma is an analyst with an average return of -6.4% and a 29.58% success rate. Sharma covers the Healthcare sector, focusing on stocks such as AstraZeneca, GlaxoSmithKline, and AstraZeneca. Currently, the analyst consensus on Philogen SpA is a Moderate Buy with an average price target of €32.00, implying a 39.13% upside from current levels. In a report released on June 25, Stifel Nicolaus also maintained a Buy rating on the stock with a €31.00 price target. The company has a one-year high of €28.00 and a one-year low of €16.10. Currently, Philogen SpA has an average volume of 165.
